Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Journal of Pharmaceutical Investigation
ISSN 2093-5552 · eISSN 2093-6214 · Springer Nature · 6 issues per year
Journal of Pharmaceutical Investigation: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.63; hybrid open access; APC about USD 3,890; median 93 days to acceptance (95 articles, last 24 months); 82 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Pharmaceutical Investigation is published by Springer Nature and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug Solubulity and Delivery Systems, Advanced Drug Delivery Systems and Analytical Methods in Pharmaceuticals, together about 38.8% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Pharmaceutical Investigation (J. Pharm. Investig.), the official journal of the Korean Society of Pharmaceutical Sciences and Technology, is an international, peer-reviewed journal that covers all pharmaceutical sciences, including engineering, regulatory, physicochemical, biological, and microbiological studies related to the conception, design, production, characterization and evaluation of pharmaceutical products and drug delivery systems. The Korean Society of Pharmaceutical Sciences and Technology (KSPST), founded in 1971, is a highly professional and scholarly organization with 1,200 members actively leading pharmaceutical research and development in academia, government, and pharma-bio industries. J. Pharm. Investig. started publication from 1971 with the launch of the KSPST, and has been indexed in Science Citation Index Expanded (SCIE) from 2021 and Scopus from 2012. All manuscript should be creative and informative for pharmaceutical scientists in academia, clinical and industrial fields. It should contain advanced knowledge in clear and concise English. Articles in the following categories are published: Research articles and Reviews. (Formerly Journal of Korean Pharmaceutical Sciences: ISSN 0259-2347)
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Editor-in-chief Dong HeePublisher website
Editorial board by country: 3 in mainland China (about 7%); most named South Korea 25, United States 6, Mainland China 3, Japan 2, Germany 1 (44 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics16.3%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics13.5%
- Analytical Methods in PharmaceuticalsChemistry9%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics7.6%
- Nanoparticle-Based Drug DeliveryMaterials Science6.5%
- Crystallization and Solubility StudiesMaterials Science4.5%
- Pharmacological Effects of Natural CompoundsPharmacology, Toxicology and Pharmaceutics4%
- Analytical Chemistry and ChromatographyChemistry3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.63LetPub ·
- Impact factor (publisher) 2025
- 4.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.5Publisher website ·
- CiteScore 2026-06
- 10.6LetPub ·
- SJR 2026-06
- 0.95LetPub ·
- SNIP 2026-06
- 1.01LetPub ·
- h-index
- 59OpenAlex ·
- i10-index
- 438OpenAlex ·
- 2-year mean citedness
- 6.17OpenAlex ·
- Self-citation rate
- 12.8%LetPub ·
- Share of gold OA articles
- 12.9%LetPub ·
Volume
- Articles per year
- 82LetPub ·
- Downloads per year (publisher) 2025
- 234,800Publisher website ·
Articles by year OpenAlex count · 1,763 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 35 | 6 | 14 |
| 2025 | 82 | 11 | 361 |
| 2024 | 62 | 11 | 729 |
| 2023 | 42 | 4 | 444 |
| 2022 | 58 | 14 | 1,735 |
| 2021 | 49 | 8 | 1,580 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
93 daysMedian, submission to acceptance · P25–P75 65 days – 114 days
- Acceptance to online
- median 20 days (95 articles)
- Submission to online
- median 109 days
- Sample
- 95 articles with submission and acceptance dates (127 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 14 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,890 / EUR 2,890 / GBP 2,490 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access publishing
Open access publishing information (fees, funding, licences) available on the Open access publishing page. Model summary
To find out more about publishing your work Open Access in Journal of Pharmaceutical Investigation, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Frequency
- 6 issues per year
- ISSN
- 2093-5552
- Electronic ISSN
- 2093-6214
- Latest issue on the website
- Volume 56, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
FAQ
Frequently asked questions about Journal of Pharmaceutical Investigation
What CAS zone is Journal of Pharmaceutical Investigation in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Pharmaceutical Investigation is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Pharmaceutical Investigation?
The latest impact factor listed by LetPub is 4.63; CiteScore 10.6, h-index 59.
How long does peer review take at Journal of Pharmaceutical Investigation?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 93 days (interquartile range 65–114 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Pharmaceutical Investigation based?
Of the 44 board members whose country the journal's board page names, 3 (about 7%) are in mainland China; the countries named most often are South Korea (25), United States (6) and Mainland China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Pharmaceutical Investigation?
According to LetPub and DOAJ records, Journal of Pharmaceutical Investigation is indexed in SCIE and Scopus. The journal's website also lists Embase, CAS and Current Contents; that list has not been checked against each database.
Is Journal of Pharmaceutical Investigation open access, and what is the APC?
Journal of Pharmaceutical Investigation is a hybrid journal. For open-access publication: APC about USD 3,890.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .